Skip to main content

Table 3 Treatment adherence outcomes in patients with acromegaly receiving octreotide or lanreotide with 180-day washout period

From: Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis

Treatment N Variable N Mean SE Minimum Maximum
Octreotide 545 Treatment time (days) 545 254.7 14.5 0 1563
  Number of injections 545 7.21 0.4 1 63
  MPR (%) 389 89 3 0.06 10
Lanreotide 118 Treatment time (days) 118 351.8 34.2 0 1454
  Number of injections 118 10.2 0.9 1 49
  MPR (%) 99 87 4 0.13 3.8
  1. N sample size, SE standard error, MPR medication possession ratio